New drug duo aims to halt silent kidney damage
NCT ID NCT00977977
Summary
This study is testing whether combining two existing drugs, rituximab and cyclosporine, is safe and more effective for treating membranous nephropathy, an autoimmune disease that damages the kidneys' filters. The goal is to reduce harmful protein loss in urine and achieve lasting remission, potentially allowing patients to stop medication. It will involve about 30 adults who have had high protein levels in their urine for at least six months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
-
National Naval Medical Center
RECRUITINGBethesda, Maryland, 20889, United States
Conditions
Explore the condition pages connected to this study.